174 related articles for article (PubMed ID: 38421520)
1. Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience.
Starace M; Rapparini L; Cedirian S; Evangelista V; Pampaloni F; Bruni F; Misciali C; Rubino D; Zamagni C; Pileri A; Piraccini BM
Support Care Cancer; 2024 Feb; 32(3):200. PubMed ID: 38421520
[TBL] [Abstract][Full Text] [Related]
2. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.
Nikolaou V; Voudouri D; Tsironis G; Charpidou A; Stamoulis G; Triantafyllopoulou I; Panoutsopoulou I; Xidakis E; Bamias A; Samantas E; Aravantinos G; Gogas H; Rigopoulos D; Syrigos K; Stratigos A
Support Care Cancer; 2019 Dec; 27(12):4535-4542. PubMed ID: 30919155
[TBL] [Abstract][Full Text] [Related]
4. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
5. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
6. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
Naqash AR; File DM; Ziemer CM; Whang YE; Landman P; Googe PB; Collichio FA
J Immunother Cancer; 2019 Jan; 7(1):4. PubMed ID: 30621779
[TBL] [Abstract][Full Text] [Related]
7. Dermatologic toxicities of targeted antineoplastic agents and immune checkpoint inhibitor therapy in pediatric patients: A systematic review.
Liu LY; Teng JMC; Spunt SL; Strelo JL; Kwong BY; Zaba LC
Pediatr Blood Cancer; 2021 Dec; 68(12):e29346. PubMed ID: 34569142
[TBL] [Abstract][Full Text] [Related]
8. Adverse cutaneous toxicities by PD-1/PD-L1 immune checkpoint inhibitors: pathogenesis, treatment, and surveillance.
Bhardwaj M; Chiu MN; Pilkhwal Sah S
Cutan Ocul Toxicol; 2022 Mar; 41(1):73-90. PubMed ID: 35107396
[TBL] [Abstract][Full Text] [Related]
9. Skin Reactions to Immune Checkpoint Inhibitors.
Patel AB; Pacha O
Adv Exp Med Biol; 2018; 995():117-129. PubMed ID: 30539508
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous adverse events caused by immune checkpoint inhibitors.
Quach HT; Johnson DB; LeBoeuf NR; Zwerner JP; Dewan AK
J Am Acad Dermatol; 2021 Oct; 85(4):956-966. PubMed ID: 34332798
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital.
Ceglio WQGW; Rebeis MM; Santana MF; Miyashiro D; Cury-Martins J; Sanches JA
An Bras Dermatol; 2022; 97(1):14-21. PubMed ID: 34844792
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
14. A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors.
Medri M; Savoia F; Foca F; Miserocchi A; Quaglino P; Rubatto M; Gullo G; Nardini C; Panasiti V; DE Tursi M; DI Marino P; Brancaccio G; Giunta EF; Napolitano S; Cinotti E; Brusasco M; Stanganelli I;
Ital J Dermatol Venerol; 2023 Dec; 158(6):437-444. PubMed ID: 38015482
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous adverse events in patients receiving anticancer therapy in a tertiary hospital setting: the old and the new.
Suh HJ; Flórez Á; Sacristán V; Rodríguez Martinez Á; Fernández F; Vilanova-Trillo L; Constenla M; Pereiro M
Int J Dermatol; 2021 Feb; 60(2):208-216. PubMed ID: 33502780
[TBL] [Abstract][Full Text] [Related]
16. Retrospective Chart Review of Cutaneous Adverse Events Associated with Tremelimumab in 17 Patients.
Welborn M; Kubicki SL; Garg N; Patel AB
Am J Clin Dermatol; 2018 Dec; 19(6):899-905. PubMed ID: 30073495
[TBL] [Abstract][Full Text] [Related]
17. Skin Reactions to Immune Checkpoint Inhibitors.
Patel AB; Pacha O
Adv Exp Med Biol; 2020; 1244():235-246. PubMed ID: 32301018
[TBL] [Abstract][Full Text] [Related]
18. Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study.
Barbu MA; Niţipir C; Voiosu T; Giurcăneanu C
Rom J Intern Med; 2018 Jun; 56(2):96-101. PubMed ID: 29360630
[TBL] [Abstract][Full Text] [Related]
19. Skin rash associated with combined cytotoxic chemotherapy and immunotherapy for cancer: A retrospective single-center case series.
Yahiro C; Takai T; Nakatani S; Tanaka N; Goto A
J Dermatol; 2023 Mar; 50(3):357-363. PubMed ID: 36258256
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
Keiser MF; Patel AB; Altan M
Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
